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The surgical management of gynecologic malignancy has tradi-
tionally been via laparotomy. Over the past few decades, the use of
laparoscopy has been increasingly incorporated into the surgical
management of gynecologic cancers. More recently, the use of robotic
surgical systems has enabled the surgeon to perform more compli-
cated procedures with improved dexterity and precision. The use of
minimal access surgery is associated less morbidity, faster recovery,
shorter hospitalization stay and increased patient satisfaction.
With the increased use of minimal access surgery in gynecologic
cancer surgery, there has been a rising concern about the complication
of recurrent disease at the laparoscopic port sites. Reymond et al.
(1998) deﬁned port-site metastasis as “early tumor recurrences that
develop locally in the abdominal wall, within the scar tissue of one
or more trocar sites or an incision wound after laparoscopy and
these should not be associated with peritoneal carcinomatosis.” Since
the ﬁrst case of port-site metastasis was described by Dobronte et al.
(1978) in 1978 after a diagnostic laparoscopy, there have been numer-
ous reports of similar cases post-laparoscopic surgery although there
is limited information available on the incidence of port site recur-
rences after robotic surgery.
The incidence of port-site metastasis after conventional laparosco-
py is reported to be about 1–2% (Ramirez et al., 2003, 2004; Zivanovic
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data on port site metastasis following robotic surgery for female gen-
ital tract cancers. Nodofor et al. (2011) reported a rate of 1.1% in a
review of 181 patients undergoing robotic surgery for gynecologic
malignancies. Other than this study, Sert (2010) described an unusual
case of robotic port-site and pelvic recurrences after robotic radical
hysterectomy for cervical cancer. Here we describe a case of port-
site metastasis after robotic surgery (robot-assisted radical hysterec-
tomy) for endometrial cancer.Case report
A72-year old,multiparouswomanwhohadnever been onhormone
replacement therapy was referred for postmenopausal bleeding. Clini-
cal examination found friable necrotic tissue at the endocervical canal
which was arising from beyond the cervix. An outpatient endometrial
biopsy conﬁrmed a poorly-differentiated adenocarcinoma. The mag-
netic resonance imaging (MRI) scan showed a uterocervical mass in-
vading more than 50% of the myometrium and involving the stroma
of the upper half of the cervix. There were no signiﬁcantly enlarged
lymph nodes on the MRI scan. The patient underwent a robot-assisted
modiﬁed radical hysterectomy with bilateral salpingo-oophorectomy,
omentectomy and pelvic lymphadenectomy. The da Vinci® surgical
system (Intuitive Surgical, Sunnyvale, CA) with 3 arms was used. In ad-
dition to the 12 mm supra-umbilical camera port, 2 instrument ports of
8 mmeachwere placed 10 cm lateral to the umbilicus on each side and
one 5 mm assistant port was placed at the right upper quadrant. This
was the ﬁfty-eighth patient undergoing robot-assisted surgery for
endometrial cancer. An intraoperative carbon dioxide (CO2) pneu-
moperitoneum of 12–14 mm Hg was maintained throughout the sur-
gery. The primary specimen being the uterus, fallopian tubes and
ovaries was removed en bloc through the vagina without using a spec-
imen bag. The lymph nodes were removed via a Lina-McCartney tube
device in the vagina. The estimated blood loss was 150mls. The histo-
pathological report diagnosis was that of a serous adenocarcinoma of
the endometrium grade 3 with more than 50% myometrial invasion
into the outer half of the myometrium, cervical stromal involvement
and extension in to the right parametrial tissue. Resection margins
were clear and there was no evidence of malignancy in the pelvic
lymph nodes, omentum or peritoneal washings. The patient was
assigned a FIGO (2009) stage of IIIB (Creasman, 2009). The patient
was offered the tumor group's recommendation of adjuvant chemo-
therapy followed by pelvic irradiation. The patient however, declined
Fig. 2. Pre-operative marking (circle) of the port-site metastasis on the left abdominal
wall.
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apy and also brachytherapy. Five months after primary treatment, dur-
ing routine clinical examination, 2 subcutaneous nodules, each about
4 cm in size, were found on the abdomen corresponding to the sites
of the (8 mm) instrument ports. A computed tomography (CT) scan
of the abdomen and pelvis showed solid-cystic lesions in the anterior
abdominal wall and tiny peritoneal nodules (Fig. 1). There was no evi-
dence of local recurrence at the vault or pelvis. A CT thorax was also
done which was unremarkable. The patient had an ultrasound-guided
ﬁne needle aspiration of the subcutaneous nodule in the right abdomi-
nal wall and the cytology of this revealed a metastatic adenocarcinoma.
She then underwent excision of both subcutaneous nodules and each
tumor was found to be 5×6 cm in size, both involving the subcutane-
ous fat, fascia and muscle (Figs. 2, 3). The tumors were excised
completely and the pathological examination found metastatic serous
adenocarcinomas with similar histological features to those seen in
the primary tumor specimen. Chemotherapy was subsequently initiat-
ed and the patient received six cycles of carboplatin and paclitaxel. A re-
peat CT scan after the third cycle of chemotherapy showed interval
resolution in the previously noted peritoneal nodules aswell as a reduc-
tion in size of the abdominal wall metastases. The patient is due to re-
ceive local radiotherapy on the metastatic sites.Discussion
In the current literature, there is a paucity of data regarding the in-
cidence of port-site metastasis after robotic surgery for gynecological
malignancy. So far, only one study by Nodofor et al. (2011) has studied
port-site metastasis after robotic procedures for suspected gynecolog-
ical malignancies and reported the incidence to be low at 1.1% (2 cases
in 181 surgeries), which is comparable to conventional laparoscopic
surgery. In that study, the ﬁrst case of port-site metastasis described
a robot-assisted hysterectomy and bilateral salpingo-oophorectomy
for a left adnexal mass and ﬁnal pathology revealed a metastatic gall-
bladder adenocarcinoma to the left ovary. The second case of port site
metastasis was an endometrial adenocarcinomametastatic to the cer-
vix and the adnexae. The patient underwent a robot-assisted total hys-
terectomy and salpingo-oophorectomy after chemotherapy and pelvic
irradiation. In each of the above cases, port-site metastasis occurred
3 weeks and 11 months respectively after the robotic surgeries.
Our case report is the ﬁrst case of port-site metastasis following
robot-assisted standard endometrial cancer staging surgery. Our pa-
tient underwent a modiﬁed radical hysterectomy, bilateral salpingo-
oophorectomy, pelvic lymphadenectomy and omentectomy. In our
patient, it is likely that the port sites were not the only sites of recur-
rence with peritoneal nodules noted on CT, although these nodules
were not histologically investigated.Fig. 1. CT scan of the abdomen showing the port-site metastases (arrows).A number ofmechanisms have been proposed for the development
of port-site metastasis including hematogenous spread, direct wound
contamination due to tumor implantation, the effects of CO2 pneu-
moperitoneum, aerosolization of tumor cells (“chimney effect”), local
immune reaction and most importantly, surgical technique. Patient
selection is also a crucial factor as more advanced disease is associated
with an increased likelihood of port-site metastasis (Pearlstone et al.,
1999).
Several preventive measures have been proposed to reduce the oc-
currence of port-site metastasis including minimizing tissue trauma
and the transfer of instruments, rinsing the trocars in povidone-
iodine and the instrument tips when changing instruments, resecting
the tumor with disease-free margins, the use of specimen bags for
retrieval, removing all intra-abdominal ﬂuid before trocar removal, ir-
rigation of trocar sites with povidone-iodine and closure of peritoneal
trocar sites of 10 mm or more. For all our robotic cases since this case,
we now routinely rinse all the trocar sites. There is also minimal
instrument change with one transfer usually during the closure of
the vault when a needle driver is substituted for the “hot shears”
monopolar scissors held in the “left hand”. In this case, the tumor
resection margins were clear as well. Perhaps for future cases, we
will implement further preventive techniques like utilizing a lower
CO2 pneumoperitoneum pressure and a protective bag for specimen
retrieval.
We started out with a practice of routinely inﬁltrating 1%marcaine
into the subcutaneous tissue as a prelude to port insertion. This was
done to improve patient analgesia. We have stopped doing this after
this case of port site metastasis. We felt that this practice could createFig. 3. Intra-operative view of port-site metastatic tumor.
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a pneumoperitoneum. We have empirically adopted this approach
based on a biologically plausible mechanism and it would be worth-
while investigating this in future studies. A subcutaneous emphysema
could also be a potential space in which tumor could seed and clinical
factors that result in the formation of a subcutaneous emphysema
could also potentially increase the risk of port site metastasis or me-
tastasis to the subcutaneous tissue. Finally, the use of powered cutting
is an aspect that could be explored in contributing to aerosolizing
the tumor and predisposing to port-site metastasis. Changes in prac-
tice were based on data gleaned from the laparoscopic literature as
port-site metastasis for robot-assisted endometrial cancer staging
has not been previously reported. We modiﬁed our practice based
on empirical derivations of possiblemechanisms for port sitemetasta-
ses such as intra-abdominal pressure and the possibility of the in-
jection of local anesthetic in the pre-peritoneal space before port
insertion creating a potential space for tumor and bacteria to seed.
Robot-assisted surgery is a relatively new treatment modality in
gynecology with the US FDA approving it for gynecological surgery
in 2005. As more gynecological procedures, both benign and for can-
cer, are performed with robot-assistance there will be an exponential
growth in clinical experience and the corresponding body of evidence
with regards to outcomes and complications. At this juncture in ro-
botic gynecological oncology surgery, it is difﬁcult to ascertain if the
risk for port-site metastasis is any different than traditional laparo-
scopic surgery as we are reporting the very ﬁrst documented case of
port-site metastasis associated with robotic surgery for endometrial
cancer staging. Although it would be reasonable to assume that
robot-assisted surgery should be no different than traditional laparos-
copy, this is an empiric observation, and an outcome that should be
continually monitored as experience with robotic surgery in endome-
trial cancer continues to increase and as this modality continues to
become ubiquitous. We hope that our case presentation contributesto this growing clinical experience, stimulates further investigation
and ultimately improves patient outcomes.
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